# Concentra Group Holdings Parent, Inc. (CON)

> Source: Nexqual · https://nexqual.com/CON · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Concentra Group Holdings Parent, Inc. (CON), nexqual.com/CON" · informational, not investment advice.

**Price:** USD 39.97 (+2.25% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 39.09 · day 38.96–40 · 52w 18.55–40 · market cap $5.10B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $2.29B, net income $199M (8.7% margin), free cash flow $267M (SEC filings).
- Valuation: P/E 25.6x (avg 14.4x at the last 2 fiscal year-ends), EV/EBITDA 14.3x, net debt $1.40B.
- 1 of 80 tracked superinvestors hold CON (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $14.6M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.82 on a 1–5 scale) (11 analysts), mean target USD 42 (range 40–47).
- Total return with dividends: 1Y +96.5% vs S&P 500 +14.9%; 5Y +78.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.44, revenue estimate $605M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.72B | $1.84B | $1.90B | $2.16B | $2.29B |
| Operating income | $259M | $288M | $305M | $334M | $375M |
| Net income | $167M | $180M | $167M | $166M | $199M |
| EPS (diluted) | $1.60 | $1.73 | $1.46 | $1.30 | — |
| Free cash flow | $228M | $169M | $210M | $197M | $267M |
| Operating margin | 15.0% | 15.6% | 16.0% | 15.4% | 16.4% |
| Net margin | 9.7% | 9.8% | 8.8% | 7.7% | 8.7% |
| Revenue growth | — | +6.6% | +3.4% | +13.9% | — |
| Cash + short-term investments | $37.7M | $31.4M | $183M | $79.9M | — |
| Total debt | — | $3.3M | $1.47B | $1.56B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 25.6x · P/S 2.2x · EV/EBITDA 14.3x · EV/Sales 2.8x · P/FCF 19.1x · P/B 10.7x · FCF yield 5.25% · Earnings yield 3.90% · Dividend yield (paid, TTM) 0.63% · Net debt $1.40B · EV $6.50B
P/E at fiscal year-ends: Dec 2025 15.2x, Dec 2024 13.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold CON. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $19.3M | Added +62.1% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Ortenzio Robert A | Director | 130,000 | $4.1M | 1.7% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Ortenzio Robert A | Director | 130,000 | $4.0M | 1.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Ortenzio Robert A | Director | 130,000 | $3.3M | 1.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Ortenzio Robert A | Director | 130,000 | $3.3M | 1.6% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.82 on a 1–5 scale), 11 analysts; mean target USD 42 (low 40, high 47).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Stephens & Co. | Initiated | Overweight | $45 |
| 2026-10-16 | Jefferies | Initiated | Buy | $47 |
| 2026-09-10 | JP Morgan | Target raised | Overweight | $34 → $43 |
| 2026-08-11 | Wells Fargo | Target raised | Overweight | $28 → $40 |
| 2026-08-10 | Truist Securities | Target raised | Buy | $37 → $42 |
| 2026-08-10 | RBC Capital | Target raised | Outperform | $36 → $42 |
| 2026-07-14 | Truist Securities | Target raised | Buy | $31 → $37 |
| 2026-07-01 | William Blair | Initiated | Outperform |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2024-07-22) |
|---|---|---|
| Total return | +96.5% | +78.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +96.9% | +29.4% |
| Volatility (annualized) | 27.7% | 27.4% |
| Max drawdown | -13.3% (Feb 2026→Apr 2026) | -20.0% (Aug 2024→Nov 2025) |

## Peers (Medical Care Facilities)
LFST (LifeStance Health Group, Inc.) USD 12.56 +1.87% · OPCH (Option Care Health, Inc.) USD 31.29 -0.00% · CHE (Chemed Corp) USD 520.15 +1.72% · NHC (National HealthCare Corporation) USD 243.07 +3.17% · PACS (PACS Group, Inc.) USD 47.5 +1.58% · ACHC (Acadia Healthcare Company, Inc.) USD 31.88 +1.43%

## More
Full page: https://nexqual.com/CON · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Reportable | $606.0M | 100.0% | +10.0% |
| — Total occupational health center revenue (part of Reportable) | $553.5M | 91.3% | +7.2% |
| — Onsite health clinics (part of Reportable) | $38.8M | 6.4% | +72.1% |
| — Other (part of Reportable) | $13.7M | 2.3% | +13.3% |
| Total revenue | $606.0M | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Workers’ compensation | $361.2M | 59.6% | +8.7% |
| Employer services | $183.2M | 30.2% | +5.1% |
| Consumer health | $6.9M | 1.1% | -4.0% |
| Other occupational health center revenue | $2.2M | 0.4% | -8.7% |
| Total revenue | $606.0M | 100% | — |
The lines above cover 91.3% of total revenue.

## Company outlook (8-K filed 2026-08-06)

- "("Concentra", the "Company", "we", "us", or "our") (NYSE: CON), the nation's largest provider of occupational health services by number of locations, today announced results for the second quarter ended June 30, 2026, declaration of a cash dividend, and raised its full-year 2026 guidance."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.44 | $0.42 | +4.5% | $605.4M | 10 |
| Next quarter (ends 2026-12-31) | $0.29 | $0.28 | +4.2% | $571.5M | 10 |
| Current fiscal year (ends 2026-12-31) | $1.65 | $1.52 | +8.2% | $2.35B | 11 |
| Next fiscal year (ends 2027-12-31) | $1.84 | $1.69 | +9.1% | $2.50B | 11 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±8.6%; last 8 reports averaged ±4.2%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 38.0% | ±8.6% |
| 2026-12-18 | 56 | 36.8% | ±11.6% |
| 2027-01-15 | 84 | 35.8% | ±13.7% |
| 2027-03-19 | 147 | 33.2% | ±16.6% |
| 2027-06-17 | 237 | 36.3% | ±22.8% |